查詢結果分析
來源資料
頁籤選單縮合
題名 | 以口服直接抗病毒藥物治療慢性C型肝炎之現況與展望--兼論「嘉義縣C肝巡迴醫療服務計畫」=Current Efficacy and Prospectives of Oral Direct-Acting Antiviral Drugs to Treat Chronic Hepatitis C |
---|---|
作者 | 羅清池; 陳美足; 黃國智; 林建宏; 鄭旭盛; 廖義堂; 洪憶雯; 盧勝男; 陳健弘; Lo, Ching-chu; Chen, Mei-tsu; Huang, Kuo-chih; Lin, Chien-hung; Cheng, Hsu-sheng; Liao, Yee-tam; Hung, I-wen; Lu, Sheng-nan; Chen, Chien-hung; |
期刊 | 內科學誌 |
出版日期 | 20181200 |
卷期 | 29:6 2018.12[民107.12] |
頁次 | 頁364-373 |
分類號 | 415.5332 |
語文 | chi |
關鍵詞 | 慢性C 型肝炎; 直接作用抗病毒藥物; 持續病毒學反應; Chronic hepatitis C; Direct-acting antiviral agent; DAA; Sustained virological response; SVR; |
中文摘要 | 慢性C型肝炎為台灣肝病排名中居高不下之主要原因之一,隨著口服直接抗病毒藥品的普及,台灣於2017年有條件給付口服直接抗病毒藥物(DAA),該年度達到很好的成效。然而儘管成效好,在台灣整體C型肝炎族群中,低於一成的人願意去診間尋求治療,因此防疫上仍有待突破。藉由擴大給付直接抗病毒藥物以及簡化治療的概念,在有限資源下,擴大篩檢以及治療普及化,期許能盡早將台灣的C型肝炎根絕弭除。 |
英文摘要 | Chronic hepatitis C is one of the main reasons for the high ranking of liver diseases in Taiwan. With the popularization of oral direct-acting antiviral drugs (DAA), DAAs have been reimbursed by the NHI, and achieved perprotocol SVR rate up to 97%. Despite good SVR rate, less than 10% of the entire hepatitis C population in Taiwan are willing to seek treatment, so there is still a great unmet need in prevention of hepatitis C. Under limited resources, we suggest a pilot project by expanding screening and treatment universalization with DAA and expect to eradicate hepatitis C in Taiwan as soon as possible. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。